Phase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 6
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the sixth newsletter from the site. This week it will be more about preclinical than clinical research, but there are still good news! We also have a podcast if you prefer to listen to the newsletter, you can find […]
Phase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/in Clinical Trial, Metastatic, Phase 3/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/in Preclinical Research/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxNew Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/in Observational, Post-hoc/by MaxMistery Solved: How Diabetes Drug Metformin Lowers Blood Sugar by Targeting Cell’s Powerhouse
/in Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
- Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors April 20, 2026